Ambler-based MBF Therapeutics, an animal health company that develops gene-based vaccines for pets, is working on a vaccine that could provide a longer-lasting immunity to COVID-19, writes Queen Muse for Philadelphia Magazine.

The company was started twelve years ago by Tom Tillett and Lorraine Keller, who wanted to make an impact in the study and development of canine cancer treatments.

“In the late 2000s, the benefits of the immunotherapy revolution were just really beginning,” said Tillett, CEO of MBF Therapeutics.

The company focused on new treatments that could manipulate the immune system in canines to fight cancer similar to how the immunotherapies and targeted therapies work for humans.

Now, the company is using the expertise gained from that research to work on what it calls a “next generation” COVID-19 vaccine.

MBF, which has created a collaboration of life science industry experts for this goal, wants to use the T-cell vaccine platform to develop a Sars-CoV-2 vaccine that could elicit a strong immune response. This would potentially work against future mutations of the virus, among other things.

“This is what’s needed in a next-generation product,” said Tillett.

Read more about MBF Therapeutics at the Philadelphia Magazine by clicking here.

You Might Also Like

FDA Places Clinical Hold on Plymouth Meeting’s Inovio’s COVID-19 Vaccine

King of Prussia-Based CSL Behring Uses AI Forecasting System to Find People with Rare Diseases

Ambler Biotech Company Working on COVID-19 Vaccine Raises $604K in Private Stock Sale